Fundraising Fox
🦊/People
Sign in

Monal Mehta

Investor

Venture Partner at Versant Ventures · Director at Endeavor Biomedicines · Board director at 858 Therapeutics, Inc.

New York City

Find your path to Monal

361 people in our graph share verified history with Monal — schools, employers, funds. One of them is your warm intro.

Sarah LucasunlockedMonal: together at Prellis (2024–2025)
Monal: together at Rutgers University
×3Monal: together at Versant Ventures
Monal: together at Navigant Consulting

About

Monal Mehta is a Venture Partner in Versant's NYC office focused on early-stage healthcare companies. She was previously a Managing Director at Avidity Partners' Private Fund and served on several biotech boards, with prior roles in business development at Pfizer and consulting at Navigant. She holds a Ph.D. in Cancer Biology.

Director at Endeavor Biomedicines

Intro paths

→

In turn, Monal can intro founders to Endeavor Biomedicines's investors below.

Endeavor Biomedicines's investors · 3

Fidelity InvestmentsBostonLongitude CapitalMenlo Park · $10M – $30M checksOmega FundsBoston · since 2021

Co-founders at Endeavor Biomedicines

JHJohn Hood
John HoodCo-Founder, Chief Executive Officer & Executive Chairman
MDMiguel de los Rios
Miguel de los RiosCo-Founder & Chief Scientific Officer

Board director at 858 Therapeutics, Inc.

Intro paths

→

In turn, Monal can intro founders to 858 Therapeutics, Inc.'s investors below.

858 Therapeutics, Inc.'s investors · 3

New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2021Versant Venture CapitalSan Francisco · since 2020Versant VenturesSan Francisco · $250K – $5M checks · since 2024

Co-founders at 858 Therapeutics, Inc.

SJStafford Jeffrey
Stafford JeffreyExecutive Officer, Director

Experience

  1. Versant VenturesVenture Partnercurrent2025 — present
  2. Prellis BiologicsBoard Member2024 — 2025
  3. Quanta TherapeuticsBoard Observer2024 — 2025
  4. MBrace TherapeuticsBoard Member2023 — 2025
  5. Endeavor BiomedicinesBoard Member2022 — 2025
  6. Avidity PartnersManaging Director2021 — 2025New York City Metropolitan Area
  7. PfizerDirector, Business Assessments2019 — 2021
  8. Pfizer OncologySenior Manager2017 — 2018New York, NY
  9. Navigant ConsultingManaging Consultant2016 — 2017NY, NY
  10. NavigantSenior Consultant2014 — 2016New York, New York
  11. The Cancer Institute of New Jersey/University of Medicine and Dentistry of New JerseyDoctoral candidate2009 — 2014
  12. IGERT/NSFFellow2012 — 2014

Skills & more

Strategic ThinkingMolecular Biology34Scientific and clinical due diligence

From Monal's professional profile.

Deals · 1

858 Therapeutics, Inc.Board seat

via Versant Ventures · filed Jul 2024 · $50.4M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Alex Mayweg
Managing Director at Versant Ventures
Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Venture Advisor at Intuitive Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures

Frequently asked questions

Who is Monal Mehta?
Monal Mehta is a Venture Partner in Versant's NYC office focused on early-stage healthcare companies. She was previously a Managing Director at Avidity Partners' Private Fund and served on several biotech boards, with prior roles in business development at Pfizer and consulting at Navigant. She holds a Ph.D. in Cancer Biology.
Where does Monal Mehta work?
Monal Mehta is Venture Partner at Versant Ventures and Board director at 858 Therapeutics, Inc..
What boards does Monal Mehta sit on?
Monal Mehta holds tracked board seats at 858 Therapeutics, Inc..
Where did Monal Mehta go to school?
Monal Mehta studied at University of Medicine and Dentistry of New Jersey (Pharmacology/ Cancer Biology); Rutgers University (Genetics); The Pingry School.

Same school

Shared employers